Earnings Call Summary | Sensus Healthcare(SRTS.US) Q2 2024 Earnings Conference
Earnings Call Summary | Sensus Healthcare(SRTS.US) Q2 2024 Earnings Conference
Adjusted EBITDA for Q2 2024 was $2.1 million, compared to negative $1 million in Q2 2023.The following is a summary of the Sensus Healthcare, Inc. (SRTS) Q2 2024 Earnings Call Transcript:
以下是Sensus Healthcare（SRTS）2024年Q2業績會電話會議摘要：
Financial Performance:
金融業績：
Sensus Healthcare reported a strong Q2 2024 with a revenue of $9.2 million, representing a 104% increase compared to $4.5 million in Q2 2023.
Net income for Q2 2024 was $1.6 million, a significant improvement from a net loss of $0.4 million in Q2 2023.
Adjusted EBITDA for Q2 2024 was $2.1 million, compared to negative $1 million in Q2 2023.
Gross profit margin improved to 58.7% in Q2 2024 from 57.9% in Q2 2023.
Sensus Healthcare在2024年Q2報告了強勁的業績，營業收入爲920萬美元，同比增長104％，相比之下2023年Q2的營收爲450萬美元。
2024年Q2淨利潤爲160萬美元，相較於2023年Q2的淨損失40萬美元有了顯著改善。
2024年Q2調整後的EBITDA爲210萬美元，而2023年Q2爲負100萬美元。
2024年Q2毛利率從2023年Q2的57.9％提升至58.7％。
Business Progress:
業務進展：
Sensus Healthcare shipped 23 SRT systems during Q2 2024, compared to 13 in the year-ago quarter, demonstrating significant growth in product demand.
They introduced the Fair Deal Agreement, a recurring revenue model, with 15 contracts signed since its launch in March 2024, projecting up to 50 by year-end.
The company made its first sale of the image-guided SRT-100 Vision system in Asia, indicating successful market expansion efforts.
Sensus Healthcare在2024年Q2運送了23台SRt系統，而去年同期僅爲13台，這表明產品需求有了顯著增長。
他們推出了Fair Deal協議，這是一種循環營收模型，自2024年3月推出以來已簽署了15份合同，並預計到年底將達到50份合同。
該公司在亞洲首次銷售指導型SRt-100 Vision系統，表明市場拓展努力取得了成功。
Opportunities:
機會：
The Fair Deal Agreement and its expected expansion to up to 50 contracts by the end of the year represent a substantial opportunity for recurring revenue growth starting 2025.
Expansion into international markets, such as Asia, demonstrates the company's growth potential outside the U.S.
Fair Deal協議以及預期到年底擴展至50份合同，代表了循環營收增長的重要機會，將從2025年開始。
拓展亞洲等國際市場展示了公司在美國以外地區的增長潛力。
Risks:
風險：
Delayed FDA response times for the approval of the TransDermal Infusion system could impact new product rollouts and revenue streams from this innovation.
FDA對TransDermal注射系統批准的反應時間延遲可能會影響該創新產品的新產品推出和營收流。
More details: Sensus Healthcare IR
更多詳情請參見Sensus Healthcare IR。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
